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Human herpesvirus 6A and 6B are β-herpesviruses approaching 100% seroprevalance
worldwide. These viruses are involved in several clinical syndromes and have important
immunomodulatory effects. Dendritic cells (DC) are key players in innate and adaptive
immunity. Accordingly, DC are implicated in the pathogenesis of many human
diseases, including infections. In this review the effects of HHV-6 infection on DC will
be discussed.
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Introduction
Human herpesvirus 6 (HHV-6) is a ubiquitous β-herpes virus that most people have been exposed
to by the age of 2 years (Okuno et al., 1989; Ward et al., 1993; Hall et al., 1994; Zerr et al., 2005).
It was ﬁrst isolated in the mid 80’s from patients with lymphoproliferative disorders and acquired
immunodeﬁciency syndrome (Salahuddin et al., 1986; Downing et al., 1987; Tedder et al., 1987).
HHV-6 isolates are classiﬁed into two distinct virus species, HHV-6A and 6B (Ablashi et al., 2014).
This review discusses the eﬀect of HHV-6 on dendritic cells (DC).
The primary infection of HHV-6 usually gives mild fever and in a limited number of cases also
a rash (Pruksananonda et al., 1992). The infection typically appear from 6 months of age, when
the immune protection from the mother vanishes and before the immune system of the child is
fully established (Stone et al., 2014). However, the virus can also cause fatal encephalitis as pri-
mary infection (Yamamoto et al., 2014), but typically this occurs only in immuno compromised
patients due to, for example, induced immunosuppression after transplantation (Zerr et al., 2012).
As an opportunistic infection the virus has been detected in diﬀerent organs like heart (Haka-
cova et al., 2013; Escher et al., 2015) and tyroidea (Caselli et al., 2012). The reactions seen during
the HHV-6 associated drug-reaction with eosinophilia and systemic symptoms syndrome show
that reactivation of the virus can occur from multiple tissues and organs (Cacoub et al., 2011).
There are also indications of involvement in CNS diseases like multiple sclerosis (Virtanen and
Jacobson, 2012) and epilepsy (Theodore et al., 2008; Esposito et al., 2014), although these results
have been diﬃcult to verify in cross-sectional studies (Gustafsson et al., 2013a; Engdahl et al.,
2014).
The viruses may have tropism for many diﬀerent cell types, including immune cells. A predom-
inant tropism is seen for CD4+ T cells (Lusso et al., 1988; Takahashi et al., 1989), but also CD8+
T cells (Lusso et al., 1991; Grivel et al., 2003), NK cells (Lusso et al., 1993), monocytes (Kondo
et al., 1991; Niiya et al., 2006), macrophages (Kondo et al., 1991), and DC (Asada et al., 1999;
Hirata et al., 2001; Kakimoto et al., 2002; Niiya et al., 2004; Takemoto et al., 2009). However, the
role of HHV-6 interactions with host DC in the pathogenic events of HHV-6 infection remains
unclear.
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Dendritic Cells
DC are a heterogeneous family of cells with specialized antigen
presenting capacities (Banchereau and Steinman, 1998; Schlitzer
and Ginhoux, 2014). They can engulf extracellular material such
as bacteria and virions, subsequently degraded in lysosomes.
DC respond to microbial stimuli, such as pathogen-associated
molecular patterns that are bound by pattern recognition recep-
tors such as toll-like receptors (TLR) (Kaisho and Akira, 2006).
DC also respond to inﬂammatory stimuli, such as inﬂamma-
tory cytokines. Microbial and inﬂammatory stimuli can initiate
a process of cellular activation termed maturation. The process
of maturation is associated with increased surface levels of MHC
and co-stimulatory molecules and other surface markers such
as CD83, as well as enhanced production of soluble inﬂamma-
tory mediators such as type I IFN, interleukin (IL)-8, IL-6, tumor
necrosis factor (TNF), and IL-12 (Ueno et al., 2007).
In the orchestration of T cells, DC interact with the TCR on
the T cells using its major histocompatibility complex (MHC)
molecules that binds antigenic peptides. The co-stimulatory
molecules CD80, CD86, and CD40 on the DC further strengthen
the interactions by binding to their ligands CD28 and CD40L
on the T cells. Upon such interaction, a so called “immuno-
logical synapse” is formed and signals are transmitted to the T
cells (Huppa and Davis, 2003). Generally, MHC class I binds
endogenous antigens (peptides) synthesized in the cells while
MHC class II binds exogenous antigens engulfed by endocytic
processes. Exogenous peptides are also presented on MHC-I in
a process called cross-presentation (Van Montfoort et al., 2014).
While DC together with B cells andmacrophages, have the ability
to express both MHC class I and class II molecules and con-
sequently interact with both CD4+ T cells and CD8+ T cells,
most other cells only express MHC class I. Viruses can hijack
the replication machinery of host cells, and hence, the virus-
infected cell displays viral peptides on its MHC class I molecules
to allow interaction with CD8+ T cells leading to killing of
the infected cells. In humans, MHC is termed human leukocyte
antigen (HLA).
The two major sub groups of DC are plasmacytoid (pDC) and
classical (cDC), and the cDC refer to all DC other than pDC
(Merad et al., 2013). Pre-cDCs derive from common DC pro-
genitors and migrate from the bone marrow via the blood and
home to lymphoid and non-lymphoid tissues (Liu et al., 2009).
Also, monocytes can diﬀerentiate into cDCs in vivo mainly in
infected or inﬂamed tissues, and therefore monocytes have been
viewed as precursors of inﬂammatory DC (Naik et al., 2006).
Recent studies, however, have established that monocytes con-
tribute to intestinal (Bogunovic et al., 2009; Varol et al., 2009),
splenic (Lewis et al., 2011), and muscular cDC also at steady state
(Langlet et al., 2012).
Although in vitro culturing of human CD34+ progenitors
with the Flt3L and thrombopoietin has proven useful in gen-
erating both pDC and cDC (Chen et al., 2004; Poulin et al.,
2010), the dominant model for the generation of human DC
has involved culturing monocytes with colony-stimulating fac-
tor 2 (CSF-2) and IL-4, which primarily produces dermal-like
CD1a+ cDC (Sallusto and Lanzavecchia, 1994; Palucka et al.,
1998). CSF-2-stimulated cultures reliably produce large num-
bers of monocyte-derived DC (MDC), which is invaluable when
designing experiments to study the functional consequences of
pathogen interactions with host DC in human infections.
Virus Replication
The vast majority of studies investigating HHV-6A or 6B infec-
tion in DC have studied MDC. The literature provides contra-
dictory reports on the replication capacity of HHV-6A (Hirata
et al., 2001; Smith et al., 2005; Gustafsson et al., 2013b) (Table 1).
Whereas, Hirata et al. (2001) suggests that DC can support HHV-
6A (U1102 strain) replication by increase in protein load over
time, Smith et al. (2005) suggests that DC cannot support HHV-
6A (GS strain) replication as no increase in intracellular viral
DNA was seen over time. We did not detect any increase in
either viral protein or DNA when infecting DC with HHV-6A
(GS strain) (Gustafsson et al., 2013b), thus supporting the report
by Smith et al. To control for degraded virus or suboptimal infec-
tions both Smith et al. and we infected susceptible cells in parallel
with DC using the same virus supernatants. Productive infection
was seen in the susceptible cells suggesting that lack of viral repli-
cation seen in DC was not due to problems with the virus stock
or infection procedure. Hence, the discordant results might lay in
other factors such as the diﬀerent viral strains or passages used.
Whereas U1102 strain showed productive infection, GS strain
did not.
For HHV-6B, the literature is more consistent. This is seen
by diﬀerent read-outs including increased virus titers in super-
natants over time (Asada et al., 1999), detection of virus proteins
using immunoﬂuoresence staining (Asada et al., 1999; Hirata
et al., 2001) or ﬂow cytometry; and detection of viral mRNA
expression (Kakimoto et al., 2002; Niiya et al., 2006; Takemoto
et al., 2009). Assessing the presence of viral proteins is some-
what problematic given the diﬃculty to discriminate between
viral proteins from the inoculum or from de novo virus synthesis,
as it is not feasible to completely wash away virus particles after
inoculation. An alternative approach is to assess shifts in levels of
viral DNA (Asada et al., 1999). Translation of early and late HHV-
6B genes has been seen, however, Takemoto et al. (2009) detected
few virions and thereby conclude that replication in DCmight be
incomplete. However, transmission to allogenic matured CD4+
T cells upon co-culture was seen, and conversion to productive
replication via cell-to-cell contact (Takemoto et al., 2009). This
was not seen for HHV-6A (Gustafsson et al., 2013b). In con-
clusion, DC seem to be able to support a productive infection
of HHV-6B and transmit the virus to T cells, constituting an
important vector for transporting the virus to the most suscep-
tible cell type. For HHV-6A, more studies are needed and the
positive result shown should be repeated using other viral strains
or clinical isolates to provide more robust proof of tropism.
Immune Modulation
HLA
Among the various aspects of immunomodulation, HHV-6 has
been suggested to impair diﬀerentiation of monocytes to DC
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(Niiya et al., 2006). The eﬀects on DC, however, remain con-
troversial (Table 1). Whereas some studies report up-regulation
of HLA class I on immature DC upon exposure to HHV-6A
or 6B, both with or without virus replication (Kakimoto et al.,
2002; Smith et al., 2005; Gustafsson et al., 2013b) others have
shown virus replication-dependent down-regulation for HHV-
6A but not for 6B (Hirata et al., 2001), and some have shown
no eﬀect at all (Niiya et al., 2006). In our hands HLA class I
expression was induced by autocrine IFN-α signaling (Gustafs-
son et al., 2013b). Two studies have investigated the expres-
sion on matured DC and demonstrated down-regulation or
unaltered expression (Smith et al., 2005; Niiya et al., 2006).
These diﬀerences are explained neither by the cell type used for
virus propagation nor by whether ultracentrifugation on virus
inoculum was used or not. Likewise, presence or absence of
virus replication cannot explain the conﬂicting results. Another
drawback in comparisons with older studies is that sometimes
the speciﬁc virus species used for a certain experiment is not
described, probably as HHV-6A and HHV-6B was recognized
as two separate viruses as late as in 2014. The same inconsis-
tency is seen for HLA class II upon HHV-6A and HHV-6B
infection where some studies report up-regulation; some report
down-regulation and some show an unaltered expression (Hirata
et al., 2001; Kakimoto et al., 2002; Smith et al., 2005; Niiya
et al., 2006; Bertelsen et al., 2010; Gustafsson et al., 2013b). To
conclude, despite the elegant pioneering study by Hirata et al.
that convincingly showed a HHV-6A exclusive suppressive eﬀect
on HLA class I, the eﬀects on HLA I/II expression does not
seem to be very strong given the varying results in subsequent
studies.
Co-stimulatory Molecules and Other Surface
Markers
Regarding co-stimulatory molecules a vast majority of studies
report conclusive data for up-regulation of CD86 and unaltered
expression of CD40 on immature DC (Kakimoto et al., 2002;
Smith et al., 2005; Niiya et al., 2006; Gustafsson et al., 2013b),
regardless of virus replication. Also for mature DC, CD86 is
up-regulated whereas CD40 expression is suppressed by both
HHV-6A and 6B (Smith et al., 2005; Bertelsen et al., 2010). For
CD80 a productive virus replication of HHV-6B seems to lead to
up-regulation in immature DC (Kakimoto et al., 2002; Niiya et al.,
2004; Bertelsen et al., 2010), whereas mature DC down-regulate
CD80 upon exposure with or without replication for both HHV-
6A and 6B (Smith et al., 2005; Bertelsen et al., 2010). CD83 is
unaltered or up-regulated upon infection with both viruses and
on both immature and matured DC. Hence, independent of pro-
ductive replication, neither HHV-6A nor 6B seems to suppress
the functions of DC on the level of co-stimulatory molecules but
rather induce maturation and activation.
Dendritic Cell-Speciﬁc Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN) and CD44 are cell surface
molecules that are important for DC homing and T cell mat-
uration. One study suggests that DC-SIGN is down-regulated
by replicating HHV-6A and 6B, as UV inactivation of the virus
prior to inoculation abrogated the suppressive eﬀect (Niiya et al.,
2004). Similarly, CD44 was suppressed or unaltered on DC upon
HHV-6 infection (Kakimoto et al., 2002; Niiya et al., 2006). Thus,
HHV-6 might have suppressive eﬀects on the ability of DC to
bind tissues such as endothelium.
Cytokines
Interferon (IFN) type I and III are important mediators of antivi-
ral immunity, secreted upon virus infection, and they have a
range of diﬀerent eﬀects. Interferon-α and -λ both signal via the
Janus kinase—signal transducers and activators of transcription
pathway but they utilize diﬀerent cell surface receptors (Shep-
pard et al., 2003; Gibbert et al., 2013).Whereas HHV-6B exposure
can induce both IFN-α and -λ secretion by pDC (Nordstrom
and Eriksson, 2012), HHV-6A exposure induces strong IFN-α,
TABLE 2 | Cytokine secretion upon HHV-6 exposure.
First author Year DC type HHV-6 spieces IFN IL-6 IL-8 IL-10 IL-12 TNF MIP-1b RANTES
Smith 2005 MDC 6A and 6B ± 6A (mat) − 6A (im) ± 6A (mat) ± 6A (mat) ± 6A (mat)
− 6B (im)
Takemoto 2009 MDC 6B + (im) + (im) + (im) + (im)
Bertelsen 2010 MDC 6B + (mat) + (mat)
Murakami 2010 MDC 6B ± (im) ± (im) ± (im)
− (mat) − (mat) − (mat)
Nordström 2012 pDC 6B + IFN-a (im)
+ IFN-g (im)
+ IFN-l (im)
Gustafsson 2013 MDC 6A + IFNa (im) ± (im) − (im) + (mat) ± (im)
± IFN-l (im) ± (mat) + (mat) + (mat)
Abbreviations used: −, downregulation upon virus exposure; +, upregulation upon virus exposure; ±, unaltered expression/secretion/effets upon virus exposure; mat, mature DC;
im, immature DC; 6A, HHV-6A; 6B, HHV-6B. Blank boxes indicate that no measurment was shown.
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but low IFN-λ secretion by MDC (Gustafsson et al., 2013b)
(Table 2).
IL-12 is involved in the diﬀerentiation of T cells toward a
Th1 lineage. Suppression of IL-12 secretion upon non-productive
infection of both HHV-6A and 6B has been shown to occur
both in DC (Smith et al., 2005) and macrophages (Smith et al.,
2003). The opposite eﬀect in DC with augmented levels has been
seen for both HHV-6A (Gustafsson et al., 2013b) and HHV-6B
(Bertelsen et al., 2010). Reasons for this divergence is unclear
but at least does not seem to lie in the procedures used for
virus propagation as the two studies demonstrating augmented
secretion used crude supernatant or ultracentrifuged virus. The
data on IL-12 described above was generated on mature DC.
In immature DC the secretions are much more modest with
a slight increase (Takemoto et al., 2009) or undetectable secre-
tion (Smith et al., 2005; Gustafsson et al., 2013b). Possibly,
therefore the role of IL-12 may not be of major importance
for immunity against HHV-6, but this needs to be investigated
further.
TNF secretion can be induced by IL-12 (Nagayama et al.,
2000). Three studies have looked at TNF secretion and report
conﬂicting results that however, at least in part, can be explained
by the IL-12 proﬁles. Whereas the single study that report mod-
est increased secretion of TNF by immature DC upon productive
HHV-6B infection also see increased IL-12 secretion (Takemoto
et al., 2009), we and others saw unaltered and nearly undetectable
levels of TNF, along with IL-12 upon non-productive HHV-6A
infection, as described above (Smith et al., 2005; Gustafsson et al.,
2013b). Hence, the diﬀerent results might be explained by the
use of diﬀerent viruses and/or virus replication. In matured DC,
however, the levels of TNF are more dramatic. In line with the
IL-12 proﬁles described above we see augmented secretion of
TNF (Gustafsson et al., 2013b) whereas Smith et al. (2005) see
unaltered or slightly decreased secretion.
IL-6 secretion is important in acute phases of inﬂamma-
tion. Whereas immature DC slightly up-regulated IL-6 secretion
upon HHV-6B infection and replication (Takemoto et al., 2009),
mature DC down-regulated secretion, due to impaired TLR4 sig-
naling (Murakami et al., 2010). For HHV-6A minute levels were
secreted by immature DC, and for mature DC the virus some-
what augmented the secretion (Gustafsson et al., 2013b). There-
fore, HHV-6B might have an exclusive ability to suppress TLR4
signaling that is not seen for HHV-6A, in terms of IL-6 secretion,
but this potential diﬀerence between the virus strains remains to
be tested.
IL-8 is a crucial cytokine which induces migration of neu-
trophils across vascular walls (Atta Ur et al., 1999). HHV-6A
has been shown to strongly suppress IL-8 secretion in imma-
ture DC, but this eﬀect was overridden when other stimuli such
as lipopolysaccharides and IFN-γ was present (Gustafsson et al.,
2013b). HHV-6B displays a mirror image with slightly enhanced
secretion by immature DC (Takemoto et al., 2009) but suppressed
secretion by mature DC (Murakami et al., 2010). As for IL-6,
described above, an exclusive ability of HHV-6B to suppress
TLR4 signaling might explain these diﬀerences.
The ability to control immune responses to restore
tissue homeostasis is crucial for the organism. IL-10 has
anti-inﬂammatory properties and suppresses secretion of
inﬂammatory cytokine and expression of HLA class II
and co-stimulatory molecules. Whereas HHV-6A inoc-
ulation does not aﬀect IL-10 secretion in mature DC
(Smith et al., 2005), inconsistent data for HHV-6B has
been published with down- or up-regulation (Bertelsen
et al., 2010; Murakami et al., 2010). Hence, additional
studies are needed to clarify the role of IL-10 in HHV-6
infection.
T Cell Stimulation
The capacities of DC to stimulate T cell expansion is crucial and
the literature is quite consistent with four out of ﬁve studies show-
ing a reduced allostimulatory capacity upon inoculation (Asada
et al., 1999; Kakimoto et al., 2002; Smith et al., 2005; Niiya et al.,
2006; Gustafsson et al., 2013b) (Table 3). This eﬀect is seen for
HHV-6A as well as for HHV-6B, regardless of virus replication,
and therefor the evidence is strong. The two studies assessing the
eﬀect on autologous T cell activation both observed an impaired
capacity upon inoculation with both HHV-6A and 6B (Kakimoto
et al., 2002; Niiya et al., 2006). This eﬀect was also seen in vivo, as
demonstrated by an elegant experiment where allogenic T cells
were co-cultured with MDC from a patients with drug induced
hypersensitivity syndrome during HHV-6 viremia and recovery
phases. The allostimulatory capacity was clearly reduced dur-
ing viremia (Niiya et al., 2006). HHV-6 also seems to possess
more indirect suppressive eﬀects by the induction of virus spe-
ciﬁc Tregs which can accomplish a suppression of the maturation
of MDC in vivo (Wang et al., 2014).
Conclusions and Future Perspectives
Altered cytokine secretion proﬁles, suppressed expression of co-
stimulatory molecules and HLA molecules and cytopathic eﬀects
TABLE 3 | Studies on allo- and autoreactivity after HHV-6 exposure of
MDC.
First author Year HHV-6
spieces
Allostimulation Autostimulation
Asada 1999 6A and 6B
(6A ns)
± 6B (im)
Kakimoto 2002 6A and 6B
(6A ns)
− (im) − (im)
Smith 2005 6A and 6B − 6A (mat)
− 6A (im)
Niiya 2006 6A and 6B − 6A (im) − (im)
− 6B (im)
Gustafsson 2013 6A − (im)
Abbreviations used:−, downregulation upon virus exposure;+, upregulation upon virus
exposure;±, unaltered expression/secretion/effets upon virus exposure; mat, mature DC;
im, immature DC; ns, not shown; 6A, HHV-6A; 6B, HHV-6B. Blank boxes indicate that no
measurment was shown.
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in response to HHV-6 may critically impact HHV-6 pathogen-
esis. The ability of DC to activate and induce proliferation of T
cells, as well as establishing appropriate cytokinemilieus required
for T cell polarization makes further studies on mechanisms
underlying the suppressive eﬀects seen by HHV-6 necessary. The
literature provides consistent results on the suppressive eﬀect of
HHV-6 on T cell proliferation. In contrast, reports on the eﬀects
on cytokine secretion and surface expression of co-stimulatory
and HLA molecules on DC are contradictory. Therefore, for
the impairment of T cell proliferation, cytokines, or surface
moleculesmay not have amajor impact butmay result from other
factors. However, to test impacts of soluble factors, conditioned
media from virus infected DC (ﬁltered to remove virions) can be
used to treat co-cultures with DC and T cells. To substantiate the
ﬁndings reported so far the data should be repeated with better
standardization of virus propagation procedures and compar-
isons between diﬀerent virus strains or clinical isolates to increase
the concordance between diﬀerent studies.
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